Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway
We showed that PEG-Loxe could decrease renal stress response and improve renal injury in T2DM by inhibiting endoplasmic reticulum stress via the GRP78/PERK/eIF2α pathway. Additionally, PEG-Loxe could hinder the TLR4/NF-κB inflammatory pathway and myocardial apoptosis and boost cardiac function, thus exerting protective effects on the cardiovascular system in T2DM.
Authors
- Junjun Zhao (ORCID: https://orcid.org/0000-0002-7772-1995)
- Yufeng Li (ORCID: https://orcid.org/0000-0002-8126-6681)
- Chen Shi (ORCID: https://orcid.org/0000-0001-8728-463X)
- Cong Wang (ORCID: https://orcid.org/0000-0002-2724-9274)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-0978-2363)
- Qilin Zhang (ORCID: https://orcid.org/0000-0002-0122-3201)
Institutions
- Hansoh Pharma (China) (CN)
- Precision for Medicine (United States) (US)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12872-024-04427-4
- Citations
- 7
- Primary Topic
- Advanced Glycation End Products research
- Type
- article
- Field-Weighted Citation Impact
- 2.67
Funders
- National Natural Science Foundation of China